Evidence map›Paper›PMID 30612162›Full record

Trial reportEuropean journal of nuclear medicine and molecular imaging2019

Olivier Humbert, Véronique Bourg, Lydiane Mondot, Jocelyn Gal, Pierre-Yves Bondiau, Denys Fontaine, Esma Saada-Bouzid, Marie Paquet, David Chardin, Fabien Almairac and 2 more

Erratum issued Registry-linked trialAbstract readClinical Trial
PubMed Publisher
In one paragraph

Trial report in European journal of nuclear medicine and molecular imaging, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. It is linked to trial NCT02022800 (Prospective Study on Oncologic Cerebral Imagery Contribution by 18F-FDOPA Position Emission Tomography), which is not on this map. Cited by 24 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
24citing papers in PubMed, 3 pooled it
4.1field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT02022800 nacompletednot on this map

Prospective Study on Oncologic Cerebral Imagery Contribution by 18F-FDOPA Position Emission Tomography (PET) in a Multidisciplinary Meeting Therapeutic Proposal When Caring for Patients Diagnosed Primary or Secondary Cerebral Tumors

TypeinterventionalSponsorCentre Antoine LacassagneRan2013 to 2016Enrolled85ConditionsGlioma, Cerebral MetastasesArmsPET 18FDOPA
3 · Its place in the literature

Who cites it

24 citing papers in PubMed, 3 syntheses or guidelines pooled it, 49 citations in OpenAlex.

  1. Guideline
  2. Pooled it
  3. Usefulness ofCancer imaging : the official publication of the International Cancer Imaging Society · 2020
    Pooled it
  4. Article
  5. Article
  6. Article
  7. Complex Diagnostic Challenges in Glioblastoma: The Role ofPharmaceuticals (Basel, Switzerland) · 2024
    Review
  8. Review
  9. Article
  10. Added value of [European journal of nuclear medicine and molecular imaging · 2023
    Article
  11. Review
  12. Impact ofJournal of nuclear medicine : official publication, Society of Nuclear Medicine · 2022
    Article
  13. Review
  14. PET Use in Cancer Diagnosis, Treatment, and Prognosis.Methods in molecular biology (Clifton, N.J.) · 2022
    Article
  15. A Clinical PET Imaging Tracer ([Clinical cancer research : an official journal of the American Association for Cancer Research · 2021
    Article
  16. Review
  17. Article
  18. HPLC-free and cassette-based nucleophilic production of [American journal of nuclear medicine and molecular imaging · 2021
    Article
  19. Clinical application ofAmerican journal of nuclear medicine and molecular imaging · 2021
    Review
  20. Integration of dynamic parameters in the analysis ofEuropean journal of nuclear medicine and molecular imaging · 2020
    Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

12 authors at 4 institutions in 3 countries.

Olivier HumbertDepartment of Nuclear Medicine, Centre Antoine-Lacassagne, Université Côte d'Azur (UCA), 33 Avenue de Valombrose, 06100, Nice, France. ohumbert@unice.fr.ORCID http://orcid.org/0000-0003-4440-5416
Véronique BourgDepartment of Neurology, Pasteur 2 University Hospital, UCA, Nice, France.
Lydiane MondotDepartment of Neuroradiology, Pasteur 2 University Hospital, UCA, Nice, France.
Jocelyn GalDepartment of Biostatistics, Centre Antoine-Lacassagne, UCA, Nice, France.
Pierre-Yves BondiauDepartment of Radiotherapy, Centre Antoine-Lacassagne, UCA, Nice, France.
Denys FontaineDepartment of Neurosurgery, Pasteur 2 University Hospital, UCA, Nice, France.
Esma Saada-BouzidDepartment of Medical Oncology, Centre Antoine-Lacassagne, UCA, Nice, France.
Marie PaquetDepartment of Nuclear Medicine, Centre Antoine-Lacassagne, Université Côte d'Azur (UCA), 33 Avenue de Valombrose, 06100, Nice, France.
David ChardinDepartment of Nuclear Medicine, Centre Antoine-Lacassagne, Université Côte d'Azur (UCA), 33 Avenue de Valombrose, 06100, Nice, France.
Fabien AlmairacDepartment of Neurosurgery, Pasteur 2 University Hospital, UCA, Nice, France.
Fanny VandenbosCentral Laboratory of Pathology, Pasteur I University Hospital, UCA, Nice, France.
Jacques DarcourtDepartment of Nuclear Medicine, Centre Antoine-Lacassagne, Université Côte d'Azur (UCA), 33 Avenue de Valombrose, 06100, Nice, France.
Centre Antoine Lacassagne · FRHôpital Pasteur · FRUniversité Côte d'Azur · FRUnited Nations Children's Fund · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeThis study aimed to assess the therapeutic impact and diagnostic accuracy of

methodsPatients with histologically proven glioblastoma or brain metastases were prospectively included in this monocentric clinical trial (IMOTEP). Patients were included either due to a clinical suspicion of relapse or to assess residual tumor infiltration after treatment. Multimodality brain MRI and

resultsOne hundred six cases were prospectively investigated by the MNTB. All patients with brain metastases (N = 41) had a clinical suspicion of recurrence. The addition of

conclusion

Indexed as

Clinical Decision-MakingInterdisciplinary CommunicationPositron Emission Tomography Computed TomographyAdultAgedAged, 80 and overBrain NeoplasmsDihydroxyphenylalanineFemaleFollow-Up StudiesGlioblastomaHumansImage Processing, Computer-AssistedMaleMiddle AgedDihydroxyphenylalaninefluorodopa F 1818F-DOPAAmino acidBrain tumoursPETTherapeutic impact

Identifiers

PMID30612162
OpenAlexW2907506640

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.